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Abstract
Background: Young female patients who receive chemotherapy frequently face premature ovarian failure (POF).
The therapeutic potential of stem cells in these patients has been explored in stem cells derived from different
sources. However, many of these types of stem cells are either difficult to obtain or obtaining them involves
invasive procedures. Here, we show that menstrual-derived stem cells (MenSCs) are easy to access and exhibit
mesenchymal stem cell-like properties. MenSCs are therefore a novel source of stem cells that can be used for
tissue repair. The aim of this study was to explore the reparative capacity and the mechanism underlying the
activities of MenSCs.
Methods: POF mouse models were established by 7 consecutive days of intraperitoneal injection of cisplatin, and
then MenSCs or MenSC-derived conditioned media (CM) were infused via the tail vein. The ovaries were excised
after either 7 or 21 days of treatment and the follicles were counted and categorized. Apoptosis of granulosa cells
was observed by terminal deoxynucleotidyl transferase mediated dUTP nick end labelling staining. Ovarian function
was evaluated by monitoring serum sex hormone levels. Furthermore, MenSC tracking, Q-PCR, and small interfering
RNA transfection were used to reveal the inner mechanism of repair.
Results: MenSC transplantation could improve the ovarian microenvironment by reducing apoptosis in granulosa
cells and the fibrosis of ovarian interstitium, which contributes to increase the follicular numbers and return sex
hormone levels to normal values. Meanwhile, the transplanted MenSCs directively migrate to ovarian interstitium to
play a role in repair rather than differentiate to oocytes directly. Additionally, MenSCs and CM derived from these
cells exerted protective effects on damaged ovaries partially by secreting FGF2.
Conclusion: MenSCs repair ovarian injury, improve ovarian function, and stimulate regeneration, suggesting that
transplantation of MenSCs may provide an effective and novel method for treating POF.
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Background
Chemotherapies, which are often used in conjunction
with surgery to treat cancer, are unquestionably benefi-
cial therapeutic agents. However, the side effects caused
by chemotherapy include damage to the ovaries in female
patients, and this effect cannot be ignored because it fre-
quently leads to premature ovarian failure/insufficiency
(POF/POI) or menopause as a direct result of its toxic
effects on follicles [1–3]. Chemotherapy can even lead to
small follicle depletion and a complete loss of oocytes.
However, there is currently no clear standard definition
for chemotherapy-induced ovarian failure, which is char-
acterized by irreversible amenorrhea in the presence of a
negative pregnancy test and follicle-stimulating hormone
(FSH) levels higher than 40 mIU/ml after chemotherapy.
A large number of female patients suffer adverse conse-
quences following chemotherapy. These can include hot
flushes, cardiovascular or neurological system disease,
osteoporosis, and sexual dysfunction. These symptoms are
dose dependent and cause a host of serious social and
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psychological problems. Hormone replacement therapy
(HRT) has been used to treat POF/POI. However, HRT
both increases the risk for recurrence of cancer [4, 5] and
fails to solve the fundamental problem. In recent years,
interest has rapidly grown in studies exploring the thera-
peutic potential of stem cells because of their potential to
differentiate into various specialized cell types. This
characteristic has been observed in stem cells derived
from a number of different sources, including bone mar-
row [6–8], amniotic fluid [9], and adipose tissue [10, 11],
and all of these cell types have been shown to have thera-
peutic effects on long-term infertility and ovarian damage.
However, many of the suitable cell types currently identi-
fied for human use are either difficult to obtain or obtain-
ing them involves invasive procedures.
Menstrual-derived stem cells (MenSCs) display mes-
enchymal stem cell (MSC)-like properties, including
self-renewal, high rates of proliferation, and multi-dif-
ferentiation capacity [12]. MenSCs can grow and adhere
in vitro and have been shown to be positive for MSC
markers [13]. Under specific conditions, MenSCs also
undergo multipotent differentiation into various func-
tional cell types, including adipocytes [14], myocytes [15],
osteocytes [16], cardiomyocytes [17], neurocytes [18, 19],
endothelial cells [20], pancreatic cells [21], and hepato-
cytes [22–25]. In autologous cell repair and regeneration,
MenSCs present major advantages over other sources of
MSCs, including ease of access and the ability to achieve
repeated sampling in a non-invasive manner. Significantly,
MenSCs exhibit low immunogenicity and possess immu-
noregulatory functions which make them safe in xenogen-
ous transplantation [26]. Hence, MenSCs are an ideal cell
type for use in treatments for tissue damage. The efficacy
of MenSCs has been demonstrated in several clinical tri-
als, including trials evaluating MenSCs as a treatment for
myocardial infarction [27], neuron system diseases
[28, 29], diabetes mellitus [30, 31], and multiple sclerosis
[32]. Because of their demonstrated differentiation cap-
acity and plasticity, we hypothesized that MenSCs may
also be useful as an alternative treatment for POF/POI.
Therefore, in this study, we injected MenSCs via the
tail vein into chemotherapy-induced POF mice and then
measured their restorative effect on ovarian function. In
addition, we further studied the mechanisms underlying
MenSC-mediated repairs.
Methods
Isolation and culture of cells
The collection of the samples used for research purposes
in this study was approved by the Ethical Committee of
The First Affiliated Hospital of Xi’an Jiantong University,
and written informed consent was obtained from each
donor. Menstrual blood (approximately 10 ml each) was
collected from six healthy women (25–30 years old) on
the first day of menstruation using a menstrual cup
(Green Donna, GuangzhouMeiFanle Rubber Products,
China). The samples were then transferred into a 50 ml
centrifuge tube containing 10 ml of phosphate-buff-
ered saline (PBS), penicillin (100 U/ml), streptomycin
(100 mg/ml), 0.25 mg/ml amphotericin B, and 2 mM
ethylenediaminetetraacetic acid (EDTA) (Gibco, Grand
Island, NY, USA). Menstrual blood mononuclear cells
were separated using Ficoll-Paque Plus (GE Healthcare,
Amersham, UK) according to the manufacturer’s instruc-
tions. The cells were suspended in a T25 flask (Corning,
New York, USA) containing DMEM/F12 supplemented
with 10% foetal bovine serum (FBS) (SiJiqing, China),
streptomycin (100 mg/ml), and penicillin (100 U/ml) and
then cultured in a humidified incubator at 37 °C in 5%
CO2. The cell culture medium was changed every 3 days.
When the cells reached 90% confluence, they were de-
tached using 0.25% trypsin–EDTA and passaged at a ratio
of 1:3.
MTT assay to evaluate cell proliferation
Cells at passages P3, P10, and P15 were seeded at
2.0 × 103 cells/well in 96-well plates (Corning) and
cultured in DMEM/F12 supplemented with 10% FBS,
streptomycin (100 mg/ml), and penicillin (100 U/ml).
On each of the following 7 days, MTT (5 mg/ml;
Sigma-Aldrich, St Louis, MO, USA) was added to the
cell medium at the same time point, and the cells
were then incubated at 37 °C for an additional 4 h. A
150-μl volume of dimethylsulfoxide (DMSO; Sigma-
Aldrich) was then added to each well to terminate
the reaction, and the blue–violet precipitate was lysed
for 15 min while shaking the solution. Absorbance
values were determined at 490 nm using an ELISA
reader (Model 680; Bio-Rad, Hercules, CA, USA). The
experiment was performed in triplicate.
Colony-forming assay
Freshly sorted cells were seeded at a very low seeding
density (150 cells/cm2) in fibronectin-coated (10 μg/ml)
60-mm cell culture dishes and cultured in stromal
medium containing DMEM/F12, 10% FBS, 2 mM glu-
tamine, and 0.5 mg/ml primocin at 37 °C in 5% CO2.
The medium was changed every 6–7 days. After 14 days,
the cells were fixed in methanol and stained using
Giemsa. Only colonies containing 50 or more cells were
defined as colony-forming units (CFU). The number of
colonies was counted according to this definition.
Flow cytometry analysis
To analyse surface marker expression using flow cytom-
etry, adherent cells (1 × 106) were harvested in 0.02%
EDTA, washed twice with PBS, and disaggregated into
single cell suspensions by pipetting. The cells were
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incubated with 10 μl of the following antibodies: fluores-
cein isothiocyanate (FITC)-conjugated mouse monoclo-
nal antibodies against CD34, CD44, CD45, CD73, and
CD90, and phycoerythrin (PE)-conjugated mouse mono-
clonal antibodies against CD49, CD133, and CD146
(Biosciences, San Jose, CA, USA) at 4 °C for 30 min.
The cells were then washed twice with PBS, resuspended
in 0.4 ml of PBS, and immediately analysed using a FACS
Calibur flow cytometer (Becton Dickinson, CA, USA).
Cell Quest software was used for the data analysis.
Cytogenetic analysis
We used cytogenetic analyses to determine the karyotypes
of MenSCs at P25. After the MenSCs were treated with
Colcemid, they were harvested using centrifugation and
washed twice with PBS. Then, 75 mM KCl was added to
the resuspended cells, and the mixture was incubated for
20 min at 37 °C. To this mixture, we added 7 drops of
chilled methanol-acetic acid fixative. The mixture was
then centrifuged for 10 min at 4 °C. The cell suspension
was dropped onto a pre-cooled slide and allowed to air
dry. The slides were then observed under a microscope.
In-vitro differentiation
Cells were differentiated into adipogenic and osteogenic
lineages to assess their differentiation capacities in vitro.
To achieve adipogenic differentiation, cells were
seeded at a density of 1 × 104 cells/cm2. After the cells
reached 80% confluence, they were incubated in adipo-
genic differentiation medium for 3 weeks. The cells were
then fixed with 4% paraformaldehyde (Sigma-Aldrich)
and stained with Oil Red O (Sigma-Aldrich). The
differentiation medium was changed every 3 days. The
adipogenic medium contained DMEM/F12, 10% FBS,
10−6 mol/L dexamethasone, 0.5 mmol/L isobutyl methyl-
xanthine, 10 μg/ml insulin, and 200 μmol/L indomethacin
(Sigma-Aldrich).
To achieve osteogenic differentiation, the cells were
seeded at a density of 2 × 103 cells/cm2. After 24 h, the
medium was replaced with osteogenic differentiation
medium, and the cells were induced for 2 weeks. The
cells were then fixed, and mineral deposition was visual-
ized using Alizarin Red (Sigma Aldrich). The osteogenic
medium contained DMEM/F12, 10% FBS, 10−8 mol/L
dexamethasone, 10 mmol/L β-glycerol phosphoric acid,
and 50 μmol/L ascorbic acid (Sigma-Aldrich).
At each experimental endpoint, the cell types of the
differentiated cells were identified using RT-PCR ana-
lysis. The specific primers used for these experiments
are presented in Table 1.
Reverse transcription and real-time qPCR
Total RNA was extracted from the cells using a RNA
Fast 200 Kit (Aidlab Biotechnology, China) according to
a standard protocol. One microgram of total RNA from
each sample was used as the template for the reverse
transcription reaction using a RevertAid First Strand
cDNA Synthesis Kit (Fermentas, USA). Real-time qPCR
was then performed using the cDNA with a SYBR
Premix Ex Taq II (Takara, China) and a CFX-96 Real-
time PCR Detection System (Bio-Rad, USA). The ampli-
fication reaction was performed using 40 cycles of the
following conditions: denaturation at 95 °C for 5 s and
annealing at 60 °C for 30 s. All gene expression levels
were normalized to the level of the internal standard
control, Gapdh, and analysed using the 2−ΔΔCt method.
The specific primers used in these experiments are pre-
sented in Table 1.
Experimental animals and animal model establishment
Female C57BL/6 mice aged 7–8 weeks were purchased
from Xi’an Jiaotong University Animal Laboratory. The
experimental protocol was approved by the Ethical
Committee and the Institutional Animal Care and Use
Committee of Xi’an Jiaotong University. The body
weight of each mouse varied from 16 to 18 g and was re-
corded every day. Vaginal smears were obtained daily.
The normal oestrous cycle in mice consists of the fol-
lowing four sequential stages: pro-oestrus, oestrus,
metoestrus, and dioestrus. These stages were determined
based on the presence or absence of leukocytes, corni-
fied epithelium, and nucleated epithelial cells [33, 34].
Additionally, only mice that went through at least two
consecutive normal oestrous cycles were included in the
experiments.
Mice were intraperitoneally injected with cisplatin
(CDDP; 2 mg/kg) for 7 consecutive days to create the
POF model.
MenSC transplantation
The mice were randomly divided into the following
three groups: control group (normal mice without any
treatment, n = 10), POF group (POF mice, n = 20), and
Table 1 Primer list
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MenSC-treated group (POF mice that were injected with
200-μl cell suspensions containing 2 × 106 MenSCs on
days 1 and 3 of the experiment, n = 20). At 7 and 21 days
after treatment was begun, the animals were sacrificed,
and serum samples and ovaries were collected for subse-
quent experiments.
Tracking GFP-labelled transplanted MenSCs
MenSCs were infected with green fluorescence protein
(GFP)-expressing lentiviral vectors (Genechem, China).
The GFP-expressing MenSCs were cultured in DMEM/
F12 supplemented with 10% FBS (SiJiqing). Before cell
transplantation, GFP expression was verified in the
MenSCs using a fluorescence microscope. The cells were
trypsinized and washed twice with PBS, and the result-
ing cell pellet was suspended in PBS to achieve a final
density of 5 × 106 cells/100 μl. Using a Hamilton syringe,
a total of 1 × 107 GFP-labelled MenSCs in 200 μl of PBS
were evenly injected into the tail veins of POF mice. At
7 and 21 days after injection, the mice were sacrificed,
and frozen sections were made from the ovaries. These
were used to investigate the morphologies and locations
of GFP-MenSCs under a fluorescence microscope
(Olympus, Japan). Nuclei were stained with DAPI.
Ria method of measuring serum hormone
To analyse ovarian function, collected serum samples
were used to measure hormone levels. We measured
serum oestradiol (E2) and FSH levels using a
[125I]Oestradiol Radioimmunoassay Kit (JiuDing, China)
and a [125I]Human FSH Radioimmunoassay Kit (JiuDing,
China) according to a standard protocol.
Ovarian follicle counts and morphologic analysis
To analyse ovarian morphology, ovaries were collected
from the three groups at 7 and 21 days after MenSC
transplantation and fixed in 4% paraformaldehyde for
12–16 h. After the ovaries were fixed, they were dehy-
drated, paraffin-embedded, serially sectioned at 5 μm
thick, and mounted on glass microscope slides. Routine
haematoxylin and eosin (H&E) staining was performed
for histologic examinations, which were analysed under
light microscopy. Follicles were categorized and counted
in every fifth section through the ovary. Follicles were
classified as follows: a primordial follicle was an oocyte
that was surrounded by a single layer of squamous gran-
ulosa cells; a primary follicle was an intact, enlarged
oocyte with a visible nucleus and one layer of cuboidal
granulosa cells; a secondary follicle possessed two or
three layers of cuboidal granulosa cells without antral
space; early antral follicles contained emerging antral
spaces; and pre-ovulatory follicles, the largest of the fol-
licular types, possessed a defined cumulus granulosa cell
layer [35].
Apoptosis assay
To detect apoptosis in the collected ovaries, terminal
deoxynucleotidyl transferase mediated dUTP nick end
labelling (TUNEL) staining kits (Roche Applied Science,
USA) were used according to the manufacturer’s instruc-
tions. The nuclei were counterstained using DAPI. Im-
ages were collected under a fluorescence microscope
(Olympus). The percentage of TUNEL-positive cells was
determined by counting five random fields from each
sample. The results are expressed as the percentages of
apoptotic cells in each section.
Conditioned medium administration in vivo
MenSCs at 80% confluence were switched to serum-free
DMEM/F12 and cultured for an additional 48 h. The
culture media were then collected as conditioned media
(CM) and concentrated 10 times using ultrafiltration
centrifuge tubes (molecular weight cut-off value: 3 kDa;
Millipore, USA).
Female C57BL/6 mice were sorted into the three fol-
lowing groups: control group (normal animals without
any treatment, n = 10), POF group (POF model, approxi-
mately 200 μl of control DMEM/F12 was injected
through the tail vein, n = 20), and CM-treated group
(POF model, approximately 200 μl of concentrated CM
was injected through the tail vein, n = 20). The mice
were sacrificed 7 days after treatment. The ovaries of the
mice were removed for H&E staining or TUNEL assays,
and serum samples were collected to measure sex hor-
mone levels.
RNA interference
Fibroblast growth factor 2 (FGF2) small interfering
RNAs (siRNAs) and negative transfection control siRNAs
(NTC) were purchased from GenePharma (China). Cells
were transfected with double-stranded siRNA oligonucle-
otides specific for FGF2 (sense sequence: 5′-GGGCA
GUAUAAACUUGGAUTT-3′, anti-sense sequence: 5′-
AUCCAAGUUUAUACUGCCCTT-3′). MenSCs were in-
cubated with 50 nM siRNA for 6 h. Lipofectamine 2000
reagent (Invitrogen, USA) was used as the transfection re-
agent. The cells were then switched to fresh DMEM/F12
media. The CM were collected after 48 hours of transfec-
tion and used for further experiments. The amount of
FGF2 secreted from the MenSCs was measured using
enzyme-linked immunosorbent assays (ELISAs).
Enzyme-linked immunosorbent assay
MenSCs were seeded at 5 × 105 cells/well in six-well
plates. Complete medium replacement was performed
when the cells reached 80% confluence. After 48 h, the
cells were harvested and spun down in a centrifuge, and
the supernatant was collected to measure the amount of
FGF2 that was secreted according to the manufacturer’s
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protocols (Ameko, China). Optical densities (OD) were
measured at 450 nm using an ELISA plate reader (Bio-
Rad, USA).
Statistical analysis
All analyses were performed using SPSS statistical soft-
ware (version 15.0; SPSS Inc., Chicago, IL, USA). The
data are expressed as the mean ± SEM from at least
three independent experiments. The significance of dif-
ferences between groups was assessed using one-way
analysis of variance (ANOVA), and P < 0.05 was consid-
ered to indicate statistical significance.
Results
Identification and characterization of MenSCs
The isolated MenSCs exhibited a fibroblast-like spindle
morphology (Fig. 1a, b) and maintained stable prolifera-
tion capacities. We found that the cells reached the
logarithmic phase within 2–6 days, while the stagnate
phase began on day 6 (Fig. 1c). To study the ability of
MenSCs to self-renew, the cells were dissociated to
form single cell suspensions and plated at low density
(150 cells/cm2). Figure 1d shows a typical cloning
dish containing colonies of varying sizes after 14 days
of culture in vitro. To assess the stability of MenSC
Fig. 1 Proliferation and colony-forming ability of MenSCs. a Morphology of primary MenSCs: passage 0. Scale bar = 100 μm. b Morphology of
passage cells: passage 3 (P3). Scale bar = 100 μm. c Growth curves for MenSCs were assessed using MTT assays. d Culture dish displaying the
distribution of colonies. e The number of colony-forming units (CFU) was counted during P3, passage 10 (P10), and passage 15 (P15). f Cytogenetic
analysis of MenSCs at passage 25
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colony-forming ability, the cells were seeded at differ-
ent passages (P3, P10, and P15). We found that there
was no significant change in colony numbers between
early and late passages (Fig. 1e). Additionally, we ana-
lysed the karyotypes of MenSCs. Even at passage 25,
the cells continued to display a normal karyotype
(Fig. 1f ).
Flow cytometry was used to identify the surface
markers expressed by MenSCs at P3 (Fig. 2a). MenSCs
expressed surface markers similar to those expressed by
MSCs. These included CD90 (97.23 ± 3.2%), CD44
(99.98 ± 1.9%), CD146 (98.72 ± 2.6%), CD49 (99.91 ± 3.3%),
and CD73 (98.10 ± 1.9%). MenSCs did not express haem-
atopoietic cell surface markers, such as CD34 (1.99 ± 0.3%),
CD45 (1.93 ± 0.1%), and CD133 (1.87 ± 1.9%).
To determine the multi-differentiation potential of
MenSCs, we cultured cells at P3 in osteogenenic or adi-
pogenic differentiation-inducing culture medium. As a
result, the cells successfully differentiated into osteo-
blasts or adipocytes, as shown by histochemical staining
(Fig. 2b, c), and expressed the correct tissue-specific
markers, as shown by qPCR (Fig. 2d). Mineral deposits
were clearly visualized when Alizarin Red staining was
used to analyse osteogenic differentiated cells. Further-
more, bone-associated genes, including SPARC and
Runx2, were up-regulated in these cells. In adipogenic
differentiated cells, lipid droplets were observed to have
accumulated when the cells were stained using Oil Red
O, and the PPARγ and FabP4 genes were up-regulated.
Treatment with MenSCs improves ovarian function in
POF mice
To investigate the effects of MenSC transplantation on
ovarian function, we recorded changes across the three
groups in body weight at various time points during the
study period (Fig. 3a). We consequently observed that
body weight was significantly higher in the MenSC-
treated group than in the POF group beginning on the
9th day after cell transplantation (Fig. 3b).
We also weighed the ovaries at 7 and 21 days after
MenSC transplantation and found that after 21 days the
ovaries obtained from MenSC-treated mice weighed sig-
nificantly more than those obtained from the mice in
the POF group (Fig. 3c). In addition, Fig. 3d shows that
ovary sizes were different across the three groups after
21 days.
Next, the ovaries in the three groups were collected
for pathological analysis. The ovaries in the POF group
were more atrophic than the ovaries in the control
group, and they exhibited a clear reduction in the num-
ber of follicles, especially primordial follicles, during
various stages of development (Fig. 3e).
Additionally, we quantified follicle numbers over
the course of each treatment. Remarkably, MenSC
transplantation substantially increased the number of
healthy follicles. After 7 days, there were significantly
more primordial follicles (316 ± 15.59), primary follicles
(176 ± 12.12), secondary follicles (64 ± 4.04), early antral
follicles (65 ± 7.51), and pre-ovulatory follicles (38 ± 2.31)
in the MenSC-treated group than in the POF group
(Fig. 3fa). After 21 days, there were significantly more pri-
mary follicles (184 ± 10.97), secondary follicles (66 ± 4.62),
and early antral follicles (71 ± 4.62) in the MenSC-treated
group than in the POF group, and more pre-ovulatory fol-
licles (36 ± 2.31) and primordial follicles (342 ± 9.81) than
in the POF group but these differences were not statisti-
cally significant (Fig. 3fb).
Serum sex hormone levels were significantly different
between the MenSC-treated group and the POF group.
At 7 and 21 days, the level of E2 was significantly higher,
while the level of FSH was lower in the group treated
with MenSCs (Fig. 3g, h).
To further explore the protective effects conferred by
MenSCs against the chemotherapy-induced loss of folli-
cles, we conducted TUNEL staining at 7 and 21 days after
cell infusion and then quantified the number of apoptotic
nuclei per total number of nuclei in each section. Interest-
ingly, TUNEL-positive GCs were clearly observed in the
POF group, and the results suggested that apoptosis was
largely restricted to the GC layer of follicles, in close prox-
imity to the oocytes. In contrast, MenSC transplantation
decreased the number of TUNEL-positive cells (Fig. 3i, j),
indicating that the MenSCs reduced injury to the ovary by
inhibiting apoptosis. Figure 3k shows the percentage of
TUNEL-positive cells that were observed in each experi-
mental group.
In-vivo MenSC tracking
As already shown, MenSCs affect the extent of ovary in-
jury. These cells may be capable of migrating towards to
the ovary. We traced the fate of injected MenSCs by
injecting mice with GFP-MenSCs. Both ovaries were
subsequently harvested from each mouse, and frozen
sections were prepared and analysed to detect the num-
ber and location of labelled cells. MenSCs transfected
with a lentivirus expressing the GFP gene efficiently and
stably expressed GFP efficiently in vitro (Fig. 4a). In the
mice, we found that GFP-positive cells were located in
the interstitium but not in follicles at 7 days after infu-
sion (Fig. 4b), and at 21 days there were no fluorescent
signals in the ovaries (Fig. 4c).
Effects of MenSC-derived CM on POF mice in vivo
As already shown, GFP-positive MenSCs were located in
the interstitium, indicating that MenSCs may not differ-
entiate to oocytes directly but that they may improve
ovarian function via other mechanisms. Previous studies
have demonstrated that MenSCs secrete a variety of
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Fig. 2 MenSCs express high levels of mesodermal antigens and display multi-lineage capacities. a Flow cytometry histograms showing the
expression level of the indicated cell surface markers on MenSCs. b Multipotent differentiation of MenSCs in vitro: osteogenic differentiation is
indicated by Alizarin Red reactivity. Scale bar = 100 μm. c Multipotent differentiation of MenSCs in vitro: adipogenic differentiation was visualized
using Oil Red staining, which reveals lipid droplets. Scale bar = 100 μm. d Differentiated MenSCs were identified using qPCR analysis to evaluate
that expression of osteogenic (SPARC and Runx2) and adipogenic (FabP4 and PPARγ) markers. Expression levels of each gene were compared with
the levels in undifferentiated MenSCs (data shown as mean ± SEM)
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cytokines that could promote the growth and renewal of
the human endometrium [36]. To investigate whether
MenSCs participate in ovarian recovery via paracrine ac-
tivity, we collected CM from cultures of MenSCs, and
then concentrated and injected them into mice (CM-
treated group). The control group was injected with an
equal volume of DMEM/F12 instead (Fig. 5a). Remark-
ably, at 7 days after injection, the levels of E2 were sig-
nificantly higher and FSH levels were significantly lower
in the CM-treated group than in the POF group (Fig. 5b
and c, respectively). In addition, a study of tissue path-
ology revealed that ovarian functions were improved and
adverse effects were ameliorated after CM administra-
tion: the ovarian fibrosis was reduced (Fig. 5d). More-
over, the rate of GC apoptosis was lower in the CM-
treated group than in the POF group (Fig. 5e).
FGF2 participates in ovarian injury repairs
To gain a further insight into the potential ovary-
reparative mechanisms underlying the functional bene-
fits observed following treatment with CM obtained
from MenSCs, we evaluated the levels of cytokines and
growth factors known to be associated with ovary rep-
arative functions. These included insulin-like growth
factor-1 (IGF-1), vascular endothelial growth factor
(VEGF), hepatocyte growth factor (HGF), fibroblast
growth factor 2 (FGF2), and granulocyte-colony stimu-
lating factor (G-CSF). We determined the level of each
markers using qPCR. Interestingly, we found that
MenSCs expressed extremely high levels of FGF2
(Fig. 6a).
To further explore the potential ovary-reparative role
of FGF2 derived from MenSCs, a siRNA was used to
Fig. 3 MenSC transplantation improves ovarian function after chemotherapy-induced injury. a Schematic of the experimental procedure used to
explore the reparative effects of MenSCs in POF mice. b Changes in body weight between three groups (data expressed as mean ± SEM, *P < 0.05).
c Changes in ovary weight across the three groups after 7 and 21 days (data expressed as mean ± SEM, *P < 0.05). d Macroscopic ovarian sizes in the
three groups after 21 days. e Representative images showing H&E-stained ovary tissue sections in each group after 7 and 21 days. Scale bars= 100 μm.
f Changes in follicle numbers in the three groups at 7 days (a) and 21 days (b) after MenSC transplantation (data expressed as mean ± SEM, *P < 0.05).
g Serum E2 levels measured in each of the three groups. h Serum FSH levels measured in each of the three groups (data expressed as mean ± SEM,
*P < 0.05). i Representative photograph showing TUNEL staining in ovary tissue sections after 7 days in each of the three groups. j Photograph
showing TUNEL staining in ovary tissue sections after 21 days in each of the three groups. TUNEL-positive cells labelled green, and nuclei
labelled blue (DAPI). Scale bars = 200 μm. k Quantitative analysis showing the percentage of TUNEL-positive cells in each group at 7 and 21 days
after treatment (data expressed as mean ± SEM, *P < 0.05). CDDP cisplatin, DAPI 4′,6-diamidino-2-phenylindole, E2 oestradiol, FSH follicle-
stimulating hormone, GFP green fluorescence protein, H&E haematoxylin and eosin, MenSC menstrual-derived stem cell, PBS phosphate-
buffered saline, POF premature ovarian failure, TUNEL terminal deoxynucleotidyl transferase mediated dUTP nick end labelling
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disrupt the expression of FGF2. FGF2 was efficiently
knocked down at the protein expression level, as shown
by ELISA, by the siRNA but not by the NTC (Fig. 6b).
When FGF2 expression was knocked down by the
siRNA, the CM obtained from MenSCs no longer sig-
nificantly increased serum levels of E2 or decreased FSH
levels (Fig. 6c, d). Moreover, the reparative effect of the
CM obtained from MenSCs on ovarian injury was also
substantially weakened: there were fewer follicles and
there was more ovarian interstitial fibrosis in the siRNA-
treated group than in the NTC group (Fig. 6e). These
data suggest that the therapeutic effect of MenSCs is
partially mediated by the secretion of FGF2.
Discussion
In the present study, we demonstrated that MenSCs iso-
lated from menstrual blood exhibit the properties of
MSCs. We explored the potential effects of MenSCs on
chemotherapy-induced ovarian damage and found that
MenSCs were able to repair ovarian injury successfully.
Previous studies have shown that MSCs can be iso-
lated from many tissues, including skin [37], adipose
tissue [10], human amniotic fluid [38], the umbilical
cord [39], and the heart [40]. MSCs have become an ex-
cellent source of seed cells that can be used for regen-
erative therapies in a variety of diseases because they
have strong self-renewal and multi-differentiation cap-
acities. However, a major drawback of these seed cells is
that they were difficult to obtain or the available quan-
tity of them is limited, which restrict their practical ap-
plications. Here, we isolated MenSCs from menstrual
blood, and we show that they possess the properties of
MSCs. Importantly, the most advantageous characteris-
tic of MenSCs, aside from their accessibility and the
need for only non-invasive isolation procedures to ob-
tain them, is the possibility that cells can periodically be
collected from the same donor. Additionally, as a result
of the low immunogenicity and the immunoregulatory
function of MenSCs, the allotransplantation of MenSCs
has successfully been applied to treatments for multiple
sclerosis, myocardial infarction and Parkinson’s disease
[32, 41, 42]. The allotransplantation of MenSCs in pa-
tients with POF can therefore also reasonably be as-
sumed to achieve success.
Fig. 4 In-vivo MenSC tracking. a GFP-MenSCs efficiently expressed GFP in vitro. b Transplanted cells were observed at 7 days after infusion, and
almost all of these cells were located in the ovarian interstitium and not in follicles. Scale bars = 100 μm. c No fluorescent signals in the ovaries at
21 days after cell transplantation. Scale bars = 100 μm. DAPI 4′,6-diamidino-2-phenylindole, GFP green fluorescence protein
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Fig. 5 (See legend on next page.)
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Higher therapeutic doses of low-passaged MenSCs
with the same genetic background can therefore be ob-
tained from each individual. Moreover, the low immuno-
genicity of MenSCs suggests that they can be used safely
in allotransplantations.
However, as a prominent source of tissues that can be
used in cell therapy, MenSCs also possess a broader
array of functional properties that might underlie their
efficacy for specific therapeutic applications. In this
study, we focused on evaluating the cellular and
(See figure on previous page.)
Fig. 5 CM obtained from MenSCs improve ovarian function following chemotherapy-induced injury. a Schematic of the experimental procedure
used to explore the reparative effects of CM in POF mice. b Serum E2 levels were measured in each of the three groups after 7 days. c Serum
FSH levels were measured in each of the three groups after 7 days (data expressed as mean ± SEM, *P < 0.05). d Representative photomicrograph
showing the results of H&E staining in each group at 7 days after injury. Scale bars = 100 μm. e Apoptosis evaluated using TUNEL staining in each
group. Scale bars = 200 μm. CM conditioned media, CDDP cisplatin, DAPI 4′,6-diamidino-2-phenylindole, E2 oestradiol, FSH follicle-stimulating
hormone, GFP green fluorescence protein, H&E haematoxylin and eosin, POF premature ovarian failure, TUNEL terminal deoxynucleotidyl transferase
mediated dUTP nick end labelling
Fig. 6 Restorative effects of MenSCs in POF are mediated via FGF2. a Relative mRNA expression levels of cytokines in MenSCs. b Cells transfected with the
FGF2 siRNA expressed significantly lower levels of FGF2, as shown by ELISA (data expressed as mean ± SEM, *P< 0.05). c Comparison of serum levels of E2
between DMEM/F12-treated, NCT-CM-treated, and si-FGF2-CM-treated mice after 7 days. d Comparison of FSH levels in DMEM/F12-treated, NTC-CM-
treated, and si-FGF2-CM-treated mice after 7 days (data expressed as mean ± SEM, *P< 0.05). e Representative images showing H&E staining after 7 days.
Lesions were more pronounced in the ovaries of si-FGF2-CM-injected mice than in mice treated with NTC-CM. Scale bars: 100 μm. CM conditioned media,
E2 oestradiol, FGF2 fibroblast growth factor 2, FSH follicle-stimulating hormone, NTC negative transfection control siRNAs, IGF-1insulin-like growth factor-1,
VEGF vascular endothelial growth factor, HGF hepatocyte growth factor), FGF2fibroblast growth factor 2, CSF colony stimulating factor
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molecular characteristics of MenSCs. The results dem-
onstrate that MenSCs feature characteristics similar to
MSCs, including an adherent spindle shape, similar sur-
face marker expression, and multi-lineage differentiation
capabilities. We have consequently focused our investi-
gation on examining the reparative effects of MenSCs.
We developed a POF mouse model using cisplatin-
induced ovarian injury, which has been shown to cause
ovarian failure in humans [1, 43]. Moreover, cisplatin in-
duces apoptosis in GCs [44], which are required for
oocyte survival and follicle development [40, 45]. After
7 days, mice that were intraperitoneally injected with
cisplatin lost a significant amount of body and ovary
weight. Histological analyses indicated that the numbers
of follicles in various stages of development were clearly
reduced. This was especially true for primordial follicles,
which stopped developing and exhibited dysmaturity. Fi-
brosis was visible in the ovarian stroma, similar to the
pathological changes that are observed in clinical cases
after treatment with chemotherapy [46]. However, after
MenSC transplantation, ovarian function significantly
improved: fibrosis was ameliorated, the number of folli-
cles was increased, apoptosis was decreased in GCs, and
hormone levels were normalized. Interestingly, we found
that while apoptosis was largely restricted to the GC
layer of follicles after POF injury, GFP-MenSCs localized
to the ovarian stroma rather than follicles, indicating
that MenSCs might migrate to the injured areas of the
ovary and repair tissues by improving and promoting
the regeneration of resident cells. This activity is most
probably mediated by paracrine effects that are initiated
in response to MenSC-secreted cytokines and growth
factors that prevent necrosis and programmed cell death.
These cytokines and growth factors may also be instru-
mental in promoting cell proliferation. We therefore
propose that the tissue salvage observed in the MenSC-
treated mice included a component of endogenous re-
generation as well as ovarian protection, and that these
activities were mainly and perhaps exclusively the result
of paracrine activity. Previous studies have demonstrated
that MSCs express distinct cytokines which enhance cell
survival, proliferation, and function and thereby exert a
positive effect on repairing tissue damage [47–49]. To
research the reparative mechanism underlying the effects
of MenSCs, we tested the effects of CM obtained from
MenSCs. The results of these experiments confirmed
that the MenSC-derived CM played a cytoprotective role
and had anti-apoptotic properties. We investigated the
expression levels of a variety of cytokines known to be
secreted by MenSCs and surprisingly found that these
cells produced much higher levels of FGF2 than other
cytokines. Among bioactive factors, FGF2 is known to
be essential for angiogenesis and for the proliferation
and remodelling of endometrial cells, and it has also
been shown to play important roles in repairing and re-
generative damaged tissues [50–52]. The concentrated
CM that were injected into the mice contained an abun-
dance of FGF2, which effectively repaired ovarian func-
tion by decreasing the fibrosis in ovarian interstitium
and promoting the growth of follicles. These effects con-
sequently improved the secretion of E2. In spite of the
fact that the expression levels of IGF-1 and HGF were
slightly higher in MenSCs, when FGF2 expression was
knocked using a siRNA the reparative activity of the
MenSCs was significantly abrogated. These results fur-
ther support the notion that the therapeutic effects of
MenSCs are likely to be partially mediated by the secre-
tion of FGF2.
Conclusions
Our research shows that MenSCs can repair ovarian in-
jury, stimulate regeneration, and improve ovarian func-
tion. Furthermore, the reparative effects of these cells
were mainly based on their paracrine mechanism by se-
creting FGF2. MenSC transplantation may provide an ef-
fective and novel method for treating POF.
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